{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:25:36Z","timestamp":1793060736548,"version":"4.5.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH\/NIAMS","award":["K23AR068447"],"award-info":[{"award-number":["K23AR068447"]}]},{"name":"NIH\/NIAMS","award":["K24AR067847"],"award-info":[{"award-number":["K24AR067847"]}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","thebonejournal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.bone.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T08:31:00Z","timestamp":1478853060000},"page":"20-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study"],"prefix":"10.1016","volume":"95","author":[{"given":"JN","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Burnett-Bowie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BZ","family":"Leder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2016.11.009_bb0005","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1359\/JBMR.050105","article-title":"Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis","volume":"20","author":"Chen","year":"2005","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.11.009_bb0010","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s00198-010-1379-y","article-title":"Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24months of treatment with teriparatide","volume":"22","author":"Blumsohn","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.11.009_bb0015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bone.2010.12.006","article-title":"PINP as an aid for monitoring patients treated with teriparatide","volume":"48","author":"Tsujimoto","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.11.009_bb0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/jbmr.251","article-title":"Effects of denosumab on bone turnover markers in postmenopausal osteoporosis","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.11.009_bb0025","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.11.009_bb0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2016.11.009_bb0035","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","article-title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2016.11.009_bb0040","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2016.11.009_bb0045","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2016.11.009_bb0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2016.11.009_bb0055","first-page":"866","article-title":"Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone","volume":"35","author":"Piemonte","year":"2012","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.bone.2016.11.009_bb0060","doi-asserted-by":"crossref","first-page":"E1848","DOI":"10.1210\/jc.2011-1534","article-title":"Acute decline in serum sclerostin in response to PTH infusion in healthy men","volume":"96","author":"Yu","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.11.009_bb0065","article-title":"Immediate effects of intermittent parathyroid hormone on circulating sclerostin levels","author":"Tsai","year":"2015","journal-title":"Endocr. Soc."},{"key":"10.1016\/j.bone.2016.11.009_bb0070","article-title":"Change in serum sclerostin after 24months of teriparatide or alendronate","author":"Yu","year":"2014","journal-title":"Am. Soc. Bone Miner. Metab."},{"key":"10.1016\/j.bone.2016.11.009_bb0075","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2014the six-month effect of risedronate and teriparatide","volume":"23","author":"Polyzos","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.11.009_bb0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","article-title":"The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1","volume":"96","author":"Gatti","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.bone.2016.11.009_bb0085","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1007\/s00198-016-3647-y","article-title":"Teriparatide and denosumab combination therapy and skeletal metabolism","volume":"27","author":"Idolazzi","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.11.009_bb0090","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1210\/jc.2013-4105","article-title":"Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa","volume":"99","author":"Fazeli","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.11.009_bb0095","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-010-9414-8","article-title":"Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1\u201334) in postmenopausal osteoporosis: association with biomarker of bone formation","volume":"87","author":"Sridharan","year":"2010","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2016.11.009_bb0100","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.11.009_bb0105","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1210\/jc.2013-1402","article-title":"Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial","volume":"98","author":"Anastasilakis","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2016.11.009_bb0110","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"key":"10.1016\/j.bone.2016.11.009_bb0115","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2016.11.009_bb0120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/bonekey.2013.95","article-title":"Clinical utility of serum sclerostin measurements","volume":"2","author":"Clarke","year":"2013","journal-title":"BoneKEy Rep."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328216303428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T20:51:40Z","timestamp":1536267100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328216303428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":24,"alternative-id":["S8756328216303428"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2016.11.009","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}